The Gpi Anchor Pathway: A Promising Antifungal Target?

References

• Cowen LE , SinghSD, KohlerJRet al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl Acad. Sci. USA106 (8), 2818–2823 (2009).
   PubMed Web of Science ®Google Scholar
• Roemer T , KrysanDJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb. Perspect. Med.4 (5), pii: a019703 (2014).
   Google Scholar
• Denning DW , BromleyMJ. Infectious disease. How to bolster the antifungal pipeline. Science347 (6229), 1414–1416 (2015).
   PubMed Web of Science ®Google Scholar
• Leidich SD , DrappDA, OrleanP. A conditionally lethal yeast mutant blocked at the first step in glycosyl phosphatidylinositol anchor synthesis. J. Biol. Chem.269 (14), 10193–10196 (1994).
   PubMed Web of Science ®Google Scholar
• Li H , ZhouH, LuoY, OuyangH, HuH, JinC. Glycosylphosphatidylinositol (GPI) anchor is required in Aspergillus fumigatus for morphogenesis and virulence. Mol. Microbiol.64 (4), 1014–1027 (2007).
   PubMedGoogle Scholar
• Umemura M , OkamotoM, NakayamaKet al. GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast. J. Biol. Chem.278 (26), 23639–23647 (2003).
   PubMed Web of Science ®Google Scholar
• Tsukahara K , HataK, NakamotoKet al. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol. Microbiol.48 (4), 1029–1042 (2003).
   PubMed Web of Science ®Google Scholar
• Mann PA , MclellanCA, KoseogluSet al. Chemical genomics-based antifungal drug discovery: targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis. ACS Infect. Dis.1 (1), 59–72 (2015).
   PubMed Web of Science ®Google Scholar
• Sagane K , UmemuraM, Ogawa-MitsuhashiK, TsukaharaK, Yoko-OT, JigamiY. Analysis of membrane topology and identification of essential residues for the yeast endoplasmic reticulum inositol acyltransferase Gwt1p. J. Biol. Chem.286 (16), 14649–14658 (2011).
   PubMedGoogle Scholar
• Hata K , HoriiT, MiyazakiMet al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob. Agents Chemother.55 (10), 4543–4551 (2011).
   PubMed Web of Science ®Google Scholar
• Eisai R&D Management Co., Ltd , Tokyo (JP) : US 769,882 B2 (2010).
   Google Scholar
• Hata K , YamamotoE, OkuboM. Physiochemical properties and nonclinical pharmacokinetics of E1211, a water-soluble prodrug of E1210. Presented at : 51st Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC)IL, USA, 17–20, September2011.
   Google Scholar
• Pfaller MA , DuncansonF, MesserSA, MoetGJ, JonesRN, CastanheiraM. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods. Antimicrob. Agents Chemother.55 (11), 5155–5158 (2011).
   PubMedGoogle Scholar
• Miyazaki M , HoriiT, HataKet al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob. Agents Chemother.55 (10), 4652–4658 (2011).
   PubMed Web of Science ®Google Scholar
• Roemer T , XuD, SinghSBet al. Confronting the challenges of natural product-based antifungal discovery. Chem. Biol.18 (2), 148–164 (2011).
   PubMedGoogle Scholar
• Xu D , JiangB, KetelaTet al. Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog.3 (6), e92 (2007).
   PubMed Web of Science ®Google Scholar
• Hong Y , MaedaY, WatanabeRet al. Pig-n, a mammalian homologue of yeast Mcd4p, is involved in transferring phosphoethanolamine to the first mannose of the glycosylphosphatidylinositol. J. Biol. Chem.274 (49), 35099–35106 (1999).
   PubMedGoogle Scholar
• Mclellan CA , WhitesellL, KingOD, LancasterAK, MazitschekR, LindquistS. Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity. ACS Chem. Biol.7 (9), 1520–1528 (2012).
   PubMed Web of Science ®Google Scholar
• Wheeler RT , KombeD, AgarwalaSD, FinkGR. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog.4 (12), e1000227 (2008).
   PubMed Web of Science ®Google Scholar
• Drogari-Apiranthitou M , MantopoulouFD, SkiadaAet al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J. Antimicrob. Chemother.67 (8), 1937–1940 (2012).
   PubMed Web of Science ®Google Scholar
• Johnson MD , MacdougallC, Ostrosky-ZeichnerL, PerfectJR, RexJH. Combination antifungal therapy. Antimicrob. Agents Chemother.48 (3), 693–715 (2004).
   PubMed Web of Science ®Google Scholar
• Watanabe N-A , HoriiT, MiyazakiM, HataK. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Presented at : 51st Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC)IL, USA, 17–20, September2011.
   Google Scholar
• Horii T , OkuboM, MiyazakiM, HataK, WatanabeN-A. In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. Presented at : 50th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC).MA, USA, 12–15 September2010.
   Google Scholar
• Anil S , EllepolaAN, SamaranayakeLP. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease. J. Oral Pathol. Med.30 (8), 481–488 (2001).
   PubMedGoogle Scholar